Labor & Human Resources
Executive Summary
At a markup scheduled for Aug. 1, committee will look at Chairman Kennedy's (D-Mass.) S 2649, a bill designed to encourage development of drug abuse treatments by offering such therapies seven years of market exclusivity in a provision modeled on the Orphan Drug Act ("The Pink Sheet" June 4, T&G-3). The bill would require HHS to look at advertising and marketing of legal drugs in the context of determining if a correlation exists between consumption of legal and illegal drugs.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.